Actively Recruiting

Phase 2
Age: 18Years - 70Years
All Genders
NCT06406114

Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing

Led by Massachusetts General Hospital · Updated on 2026-03-19

300

Participants Needed

6

Research Sites

190 weeks

Total Duration

On this page

Sponsors

M

Massachusetts General Hospital

Lead Sponsor

N

National Institute of Allergy and Infectious Diseases (NIAID)

Collaborating Sponsor

AI-Summary

What this Trial Is About

Cephalosporin antibiotics are commonly used but can result in allergic reactions and anaphylaxis. There is no clear diagnostic approach for cephalosporin-allergic patients, and guidance for the use of other antibiotics in allergic patients is based on side chain chemical similarity and limited skin testing evidence. This project includes a clinical trial and mechanistic studies to optimize the approach to cephalosporin allergy and advance future diagnostics.

CONDITIONS

Official Title

Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing

Who Can Participate

Age: 18Years - 70Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 18 to 70 years old
  • History of immediate allergic reaction symptoms to specified cephalosporin antibiotics
  • English speaking or with available translation services
Not Eligible

You will not qualify if you...

  • Severe medical conditions such as unstable coronary artery disease, congestive heart failure, severe COPD, poorly controlled asthma, chronic renal failure, cirrhosis, or end-stage liver disease
  • History of Clostridioides difficile infection
  • Chronic spontaneous urticaria or systemic mastocytosis
  • Prior reaction requiring cardiopulmonary resuscitation
  • Allergy to two or more cephalosporin antibiotics
  • Active infection or antibiotic use within 7 days
  • Use of systemic antihistamines or corticosteroids within 7 days
  • Treatment with omalizumab or dupilumab within 60 days
  • Significant immunosuppression
  • Use of beta-blockers or ACE inhibitors within 7 days
  • Participation in investigational drug studies within 60 days
  • Anaphylaxis in the last 30 days
  • Penicillin anaphylaxis within the past year confirmed by skin testing
  • Prison or jail inmates, pregnant women, or severe cognitive impairment
  • Current diagnosed mental illness or drug/alcohol abuse interfering with participation
  • Other medical problems or laboratory findings posing risks or interfering with study compliance
  • Inability or unwillingness to give informed consent or comply with study protocol

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 6 locations

1

Mayo Clinic Arizona

Scottsdale, Arizona, United States, 14607

Actively Recruiting

2

University of California, San Francisco

San Francisco, California, United States, 94143

Actively Recruiting

3

Massachusetts General Hospital

Boston, Massachusetts, United States, 02114

Actively Recruiting

4

Rochester General Hospital

Rochester, New York, United States, 14621

Actively Recruiting

5

Vanderbilt University Medical Center

Nashville, Tennessee, United States, 37232

Actively Recruiting

6

University of Texas Southwestern Medical Center

Dallas, Texas, United States, 75390

Actively Recruiting

Loading map...

Research Team

C

Cara Yelverton, BSc, PhD

CONTACT

K

Kell Lopez, BS

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

CROSSOVER

Primary Purpose

DIAGNOSTIC

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here